BR TD 1001
Alternative Names: BR-TD-1001Latest Information Update: 29 Nov 2022
At a glance
- Originator Boryung Biopharma
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diphtheria; Tetanus
Most Recent Events
- 29 Nov 2022 No development reported - Phase-III for Diphtheria (In children) in South Korea (IM) (NDR Batch 25)
- 29 Nov 2022 No development reported - Phase-III for Tetanus (In children) in South Korea (IM) (NDR Batch 25)